Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11897-017-0327-y http://scihub22266oqcxt.onion/10.1007/s11897-017-0327-y C5645149!5645149 !28281174     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28281174 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Heart+Fail+Rep 2017 ; 14 (2 ): 134-145 Nephropedia Template TP {{tp|p=28281174 |t=2017. Potential Expanded Indications for Neprilysin Inhibitors |pdf=|usr=}}{{28281174 }} gab.com Text Potential Expanded Indications for Neprilysin Inhibitors JO: Curr Heart Fail Rep http://www.kidney.de/pget.php?&tw=1&pmid=28281174 #FOAvip PURPOSE OF REVIEW: The goal of this article is to review potential expanded indications for neprilysin inhibitors. This article reviews the rationale and design for ongoing and future trials of sacubitril/valsartan in cardiovascular and non-cardiovascular disease. RECENT FINDINGS: Randomized trial data are lacking for use of sacubitril/valsartan in acute heart failure and advanced heart failure. Mechanistic data from animal studies suggest a role for neprilysin inhibition in the treatment of post-myocardial infarction systolic dysfunction and heart failure with preserved ejection fraction. Beyond the cardiovascular system, renal and neurological function may be impacted by neprilysin inhibition. Forthcoming randomized trials will address the clinical impact of sacubitril/valsartan on these conditions. Neprilysin inhibition with sacubitril/valsartan offers a new therapeutic strategy with a broad range of potential therapeutic actions. In PARADIGM-HF, the combination of neprilysin and RAAS inhibition was proven to be superior to enalapril for patients with stable NYHA class II-III heart failure and reduced left ventricular ejection fraction. Preliminary data suggests it may also have a role in other cardiovascular and non-cardiovascular disease. Several ongoing and planned studies will determine the extent of its benefit for these other indications. Twit Text FOAVip Potential Expanded Indications for Neprilysin Inhibitors ????Curr Heart Fail Rep http://www.kidney.de/pget.php?&tw=1&pmid=28281174 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28281174 #FOAvip English Wikipedia <ref>{{Cite pmid|28281174 }}</ref> Potential Expanded Indications for Neprilysin Inhibitors #MMPMID28281174 Riddell E ; Vader JM Curr Heart Fail Rep 2017[Apr]; 14 (2 ): 134-145 PMID28281174 show ga PURPOSE OF REVIEW: The goal of this article is to review potential expanded indications for neprilysin inhibitors. This article reviews the rationale and design for ongoing and future trials of sacubitril/valsartan in cardiovascular and non-cardiovascular disease. RECENT FINDINGS: Randomized trial data are lacking for use of sacubitril/valsartan in acute heart failure and advanced heart failure. Mechanistic data from animal studies suggest a role for neprilysin inhibition in the treatment of post-myocardial infarction systolic dysfunction and heart failure with preserved ejection fraction. Beyond the cardiovascular system, renal and neurological function may be impacted by neprilysin inhibition. Forthcoming randomized trials will address the clinical impact of sacubitril/valsartan on these conditions. Neprilysin inhibition with sacubitril/valsartan offers a new therapeutic strategy with a broad range of potential therapeutic actions. In PARADIGM-HF, the combination of neprilysin and RAAS inhibition was proven to be superior to enalapril for patients with stable NYHA class II-III heart failure and reduced left ventricular ejection fraction. Preliminary data suggests it may also have a role in other cardiovascular and non-cardiovascular disease. Several ongoing and planned studies will determine the extent of its benefit for these other indications. |Aminobutyrates/*therapeutic use [MESH] |Angiotensin Receptor Antagonists/*therapeutic use [MESH] |Animals [MESH] |Biphenyl Compounds [MESH] |Drug Combinations [MESH] |Drug Therapy, Combination [MESH] |Heart Failure/*drug therapy [MESH] |Humans [MESH] |Neprilysin/*antagonists & inhibitors [MESH] |Tetrazoles/*therapeutic use [MESH]Potential Expanded Indications for Neprilysin Inhibitors (epmc).pdf DeepDyve Pubget Overpricing